Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adi Diab

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2006
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantationMiguel-Angel Perales, Adi Diab, Adam D Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
Cancer|November 1, 2021
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefitAnisha B Patel, Sahira Farooq, Macartney Welborn, et al.
Plos One|December 19, 2013
Enhanced responses to tumor immunization following total body irradiation are time-dependentAdi Diab, Robert R Jenq, Gabrielle A Rizzuto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Scott S Tykodi, Gregory A Daniels, et al.
NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.
Nature Communications|February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonistGiulia Parisi, Justin D Saco, Felix B Salazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020
Circulating Tumor Cells and Early Relapse in Node-positive MelanomaAnthony Lucci, Carolyn S Hall, Sapna P Patel, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2006
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantationMiguel-Angel Perales, Adi Diab, Adam D Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
Cancer|November 1, 2021
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefitAnisha B Patel, Sahira Farooq, Macartney Welborn, et al.
Plos One|December 19, 2013
Enhanced responses to tumor immunization following total body irradiation are time-dependentAdi Diab, Robert R Jenq, Gabrielle A Rizzuto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Scott S Tykodi, Gregory A Daniels, et al.
NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.
Nature Communications|February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonistGiulia Parisi, Justin D Saco, Felix B Salazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020
Circulating Tumor Cells and Early Relapse in Node-positive MelanomaAnthony Lucci, Carolyn S Hall, Sapna P Patel, et al.
Pageof 14